Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation

Anjali S. Golocheikine; Deepti Saini; Sabarinathan Ramachandran; Elbert P. Trulock; Alexander Patterson; T. Mohanakumar

doi:10.1016/j.trim.2007.07.007

Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation

Anjali S. Golocheikine, Deepti Saini, Sabarinathan Ramachandran, Elbert P. Trulock, Alexander Patterson, T. Mohanakumar

Surgery

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The long term survival of human lung allograft is hampered by the occurrence of chronic rejection, Bronchiolitis Obliterans Syndrome (BOS). This end-stage disease is normally diagnosed clinically by using the pulmonary function tests. This results in delay of BOS diagnosis and consequently prevents early intervention. It is generally accepted that alloimmunity plays an important role in chronic rejection of the allograft. In this study we analyzed serial serum samples from BOS+ and BOS- patients for sCD30 levels to determine the role of sCD30 to predict the onset of BOS. In contrast to BOS negative patients and normal subjects, 6 out of 9 BOS+ patients (p < 0.05) studied had an increase in the sCD30 levels. Significantly, the rise was noted 7.57 ± 2.63 months before the clinical diagnosis was evident. Therefore, we propose that the rise in serum sCD30 levels can be used as a marker for the detection of patients who are at risk of development of BOS.

Original language	English (US)
Pages (from-to)	260-263
Number of pages	4
Journal	Transplant Immunology
Volume	18
Issue number	3
DOIs	https://doi.org/10.1016/j.trim.2007.07.007
State	Published - Jan 2008

Bibliographical note

Funding Information:
This work was supported by NIH/NHLBI HL56543 (TM). The authors would like to thank Nancy Steward and Aviva Aloush for the technical assistance, and Billie Glasscock for the assistance in preparing this manuscript.

Keywords

Bronchiolitis obliterans syndrome (BOS)
Chronic rejection
FEV1
Lung transplantation
sCD30

Access

10.1016/j.trim.2007.07.007

OpenUrl availability

Full text

Cite this

@article{42069831a46645618d9da1b9f6d05df2,

title = "Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation",

abstract = "The long term survival of human lung allograft is hampered by the occurrence of chronic rejection, Bronchiolitis Obliterans Syndrome (BOS). This end-stage disease is normally diagnosed clinically by using the pulmonary function tests. This results in delay of BOS diagnosis and consequently prevents early intervention. It is generally accepted that alloimmunity plays an important role in chronic rejection of the allograft. In this study we analyzed serial serum samples from BOS+ and BOS- patients for sCD30 levels to determine the role of sCD30 to predict the onset of BOS. In contrast to BOS negative patients and normal subjects, 6 out of 9 BOS+ patients (p < 0.05) studied had an increase in the sCD30 levels. Significantly, the rise was noted 7.57 ± 2.63 months before the clinical diagnosis was evident. Therefore, we propose that the rise in serum sCD30 levels can be used as a marker for the detection of patients who are at risk of development of BOS.",

keywords = "Bronchiolitis obliterans syndrome (BOS), Chronic rejection, FEV1, Lung transplantation, sCD30",

author = "Golocheikine, {Anjali S.} and Deepti Saini and Sabarinathan Ramachandran and Trulock, {Elbert P.} and Alexander Patterson and T. Mohanakumar",

note = "Funding Information: This work was supported by NIH/NHLBI HL56543 (TM). The authors would like to thank Nancy Steward and Aviva Aloush for the technical assistance, and Billie Glasscock for the assistance in preparing this manuscript.",

year = "2008",

month = jan,

doi = "10.1016/j.trim.2007.07.007",

language = "English (US)",

volume = "18",

pages = "260--263",

journal = "Transplant Immunology",

issn = "0966-3274",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation

AU - Golocheikine, Anjali S.

AU - Saini, Deepti

AU - Ramachandran, Sabarinathan

AU - Trulock, Elbert P.

AU - Patterson, Alexander

AU - Mohanakumar, T.

N1 - Funding Information: This work was supported by NIH/NHLBI HL56543 (TM). The authors would like to thank Nancy Steward and Aviva Aloush for the technical assistance, and Billie Glasscock for the assistance in preparing this manuscript.

PY - 2008/1

Y1 - 2008/1

N2 - The long term survival of human lung allograft is hampered by the occurrence of chronic rejection, Bronchiolitis Obliterans Syndrome (BOS). This end-stage disease is normally diagnosed clinically by using the pulmonary function tests. This results in delay of BOS diagnosis and consequently prevents early intervention. It is generally accepted that alloimmunity plays an important role in chronic rejection of the allograft. In this study we analyzed serial serum samples from BOS+ and BOS- patients for sCD30 levels to determine the role of sCD30 to predict the onset of BOS. In contrast to BOS negative patients and normal subjects, 6 out of 9 BOS+ patients (p < 0.05) studied had an increase in the sCD30 levels. Significantly, the rise was noted 7.57 ± 2.63 months before the clinical diagnosis was evident. Therefore, we propose that the rise in serum sCD30 levels can be used as a marker for the detection of patients who are at risk of development of BOS.

AB - The long term survival of human lung allograft is hampered by the occurrence of chronic rejection, Bronchiolitis Obliterans Syndrome (BOS). This end-stage disease is normally diagnosed clinically by using the pulmonary function tests. This results in delay of BOS diagnosis and consequently prevents early intervention. It is generally accepted that alloimmunity plays an important role in chronic rejection of the allograft. In this study we analyzed serial serum samples from BOS+ and BOS- patients for sCD30 levels to determine the role of sCD30 to predict the onset of BOS. In contrast to BOS negative patients and normal subjects, 6 out of 9 BOS+ patients (p < 0.05) studied had an increase in the sCD30 levels. Significantly, the rise was noted 7.57 ± 2.63 months before the clinical diagnosis was evident. Therefore, we propose that the rise in serum sCD30 levels can be used as a marker for the detection of patients who are at risk of development of BOS.

KW - Bronchiolitis obliterans syndrome (BOS)

KW - Chronic rejection

KW - FEV1

KW - Lung transplantation

KW - sCD30

UR - http://www.scopus.com/inward/record.url?scp=36348989633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348989633&partnerID=8YFLogxK

U2 - 10.1016/j.trim.2007.07.007

DO - 10.1016/j.trim.2007.07.007

M3 - Article

C2 - 18047935

AN - SCOPUS:36348989633

SN - 0966-3274

VL - 18

SP - 260

EP - 263

JO - Transplant Immunology

JF - Transplant Immunology

IS - 3

ER -

Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this